21st Austria weekly - Marinomed 07/02/2024 [pic1]Marinomed: Biotech AG has enrolled the first patient in a clinical study to investigate lubricating properties of Carragelose eye drops patients diagnosed with mild moderate dry disease. While product holds valid certification under Medical Device Directive MDD supports switch new Regulation MDR. are planned launch 2024. Furthermore business development process for partnering outside is full swing. Next drops also allergen-blocking nasal spray published data demonstrating effectiveness prophylactic treatment allergic rhinitis symptoms nose on pre-print server October
EQS-News: Marinomed Biotech AG with important progress for Carragelose in 2024 finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.
EQS-News: Marinomed Biotech AG / Key word: Study/Patent
Marinomed Biotech AG with important progress for Carragelose in 2024
07.02.2024 / 07:45 CET/CEST
The issuer is.
21st Austria weekly - ATX TR at 7661.61 Mayr-Melnhof AT&S and Andritz best-performing Kapsch TrafficCom with weakest performance 27/01/2024 [pic1]A very good week for TR which gained 3 32 percent to 7.661 61 points this means also that we are now in the profit zone 2024. Wienerberger is 7 days a row up AT&S was last best stock from our Private Investor Relations Universe. News came AT&S Lenzing Andritz Vienna Airport Frequentis